Kimberlee Adams
Psychiatric/Mental Health · Newark, DENPI 1831257765
Payments from drug & device makers
Across 12 payments — averaging $30.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$125
- Otsuka America Pharmaceutical, Inc.$73
- Xeris Pharmaceuticals, Inc.$33
- Ultragenyx Pharmaceutical Inc.$21
- Takeda Pharmaceuticals U.S.A., Inc.$19
- Protega Pharmaceutials Inc$16
- plus $75 from 5 others
What the payments were for
- Food & beverage$363100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $73 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Protega Pharmaceutials Inc | 1 | $16 |
| Vertex | 1 | $16 |
| Harmony Biosciences LLC | 1 | $16 |
| Orexo US, Inc. | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| CSL Behring | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$125
How this compares
$363 in reported general payments places this provider in the 40th percentile of 177 psychiatric/mental health providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Potassium | 11 | $26,869 |
| JanuviaSitagliptin Phosphate | 22 | $11,985 |
| Oxycodone Hcl | 418 | $8,216 |
| OxycontinOxycodone Hcl | 24 | $5,329 |
| Xtampza ErOxycodone Myristate | 20 | $4,807 |
| VascepaIcosapent Ethyl | 19 | $4,408 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $4,337 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 108 | $2,901 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $1,728 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 56 | $1,604 |
| Naloxone Hcl | 18 | $1,267 |
| Gabapentin | 120 | $912 |
| Diclofenac Sodium | 46 | $674 |
| Atorvastatin Calcium | 60 | $408 |
| Tramadol Hcl ErTramadol Hcl | 11 | $399 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Newark
- Kameka HartNewark$10K
- Bradley WhyNewark$6K
- Ema SohnaNewark$5K
- Kareemah HammondNewark$4K
- Tiffany DysonNewark$3K
- Bernadette MomohNewark$3K
- Stefanie FerraroNewark$2K
- Catherine LukoNewark$2K
- Ronald TyreeWilmington$59K
- Ericka Taylor-DanielDover$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.